Mauri et al Cancer Treat Rev 2010; Schröder et al EJC 2011
Docetaxel and paclitaxel in 1L (best schedule)
•
weekly paclitaxel
80-100 qw3/4
better OS than three-weekly group
175
(HR 0.78, 5 RCTs, N=1,471
patients)
•
ORR better in three-weekly group (RR 1.20, 7 RCTs; N=1,772 patients)
•
NS for PFS (6 RCTs)
Paclitaxel
Docetaxel
•
NS differences (3 RCTs; N=231 patients) for OS, PFS (2 RCTs) or ORR (3 RCTs)
•
The use of weekly paclitaxel regimens is therefore recommended for the treatment of locally
advanced/metastatic BC
•
Weekly docetaxel is less well tolerated than a 3-weekly
schedule, due to >non-haematological toxicity (nail
changes, EPP, epifora, fatigue and general malaise),
despite less febrile neutropenia (and peripheral
neuropathy)
•
No efficacy benefits can be demonstrated for weekly
docetaxel
3-weekly schedule should be preferred in
the setting of MBC
•
Multicenter Rx phase III (N=162, aprox
25% 1L)
•
Pimary endpoint tolerability
•
NS in ORR, DoR, or PFS and better TTF
for doce (HR 0.67*)
•
3w doce better OS (HR 0.70*) not in
univariate analysis
